GENE ONLINE|News &
Opinion
Blog

2022-05-18| FundingR&D

Evotec Leverages Sernova’s Cell Pouch to Develop Diabetes Stem Cell Treatment

by Reed Slater
Share To

Evotec, a Germany-based induced pluripotent stem cells (iPSC) development company, made a €15 million equity investment in Sernova to establish a strategic partnership to leverage Sernova’s Cell Pouch System technology to develop a “functional cure” for insulin-dependent diabetes. Sernova confirmed it will receive an additional €5 million equity investment by August 31, 2022.

 

Terms and Conditions of the Partnership

 

In addition to the €20 million investment, Sernova acquired an option for an exclusive global license to Evotec’s iPSC-based beta cells (cells that make insulin) to treat patients with insulin-dependent diabetes. The two companies will jointly fund the preclinical developments until the FDA accepts an Investigational New Drug Application (IND). After the IND acceptance, Sernova will have the right to exercise the global license. Sernova and Evotec will discuss the terms of joint funding again if the drug is commercialized. 

Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, said, “We searched long and hard for the right partner. Sernova clearly ticks all boxes with their clinically validated Cell Pouch™ technology, which fits perfectly to Evotec’s iPSC-based beta cells.”

Dr. Dohrmann will join Sernova’s board of directors as part of the partnership. With over 25 years of experience, the strategic addition of Dr. Dohrmann is sure to add substance to the partnership. 

 

Related Article: Evotec Expands Partnership with Bristol Myers Squibb for Potential $5 Billion Deal

 

Filling Sernova’s Cell Pouches With Evotec’s Beta Cells

 

Evotec said in the announcement that the partnership will leverage the use of iPSC-based beta cells from its QRbeta initiative. The beta cells in question are designed to be functionally equivalent to human islets in normalizing blood glucose. Islets are micro-organs in the body that regulate glucose homeostasis. Evotec said the iPSC-based technology has shown promise in several in vivo models. 

The other half of the partnership includes Sernova’s Cell Pouch technology, an implantable and scalable medical device that provides a natural environment in the body for housing and long-term survival and function for therapeutic cells. The Cell Pouch is approved by the FDA for permanent use in the human body and is currently undergoing a Phase 2 clinical trial including 7 participants. The study completion date is set for July 2023.

With Sernova’s proprietary Cell Pouch technology and Evotec’s beta cells, the two hope to provide a beta cell replacement therapy that could produce unlimited insulin-producing cells. This breakthrough has the potential to provide a favorable treatment alternative for diabetes patients who regularly undergo insulin injections. 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Novo Nordisk Acquire Catalent for $16.5 Billion, Enhancing Obesity Drugs Production Capacity
2024-02-07
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
Breakthrough Stem Cell Treatment Shows Promise in Reversing Liver Disease
2023-12-08
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top